International Journal of Drug Delivery Technology
Volume 16, Issue 12s, 2026

Formulation And Evaluation Of Nanostructured Lipid Carrier Loaded Topical Formulation Of Naringenin For Healing Of Wounds

Tanveer Khan1*, Ashish Jain1

1LNCT University, J.K. Town, Kolar Road, Sarvadharam C Sector, Bhopal, Madhya Pradesh, India-462042

*Corresponding Author: Tanveer Khan, LNCT University, J.K. Town, Kolar Road, Sarvadharam C Sector, Bhopal, Madhya Pradesh, India-462042. Email: tanutanveer12@gmail.com


ABSTRACT

Background: Naringenin (NRG) is a plant based flavanone that can kill microbes, work as an antioxidant, reduce inflammation, and help wounds heal. However, it has poor water solubility and limited uptake (5–8%), which limits its possible uses in medicine when applied to skin. Nanostructured lipid carriers (NLCs) are a potential way to get around these problems by making lipophilic drugs more soluble and stable and controlling their release.

Methods: NLCs were made using stearic acid (a solid lipid), oleic acid (a liquid lipid), and Tween 80 (a detergent) in a study using the emulsion-sonication method. They were then prepared into a cream base for topical application. The NLC-loaded cream had good physicochemical qualities, were uniform, had a pH of 6.02 ± 0.033, viscosity of 517 ± 17.3 cp, spreadability of 46.7 ± 1.14 mm, and drug content of 96.2 ± 1.03%.

Results: In rats were used for in vivo excision wound studies, the wounds healed much faster—96% closure by day 10 and full contraction by day 15.

Conclusion: These results show that NLC-based topical formulations of NRG make things more stable, release them in a controlled way, and heal wounds better. This shows that they could be used as advanced therapeutic systems for dermatological uses.

Keywords: Wound healing, Naringenin, Nanostructured lipid carrier, topical application, excision model

How to cite this article: Khan T, Jain A. Formulation and evaluation of Nanostructured Lipid Carrier loaded topical formulation of Naringenin for healing of wounds. Int J Drug Deliv Technol. 2026;16(12s): 753-757. DOI: 10.25258/ijddt.16.12s.89

Source of support: Nil.

Conflict of interest: None